References
- Adam F, Quesada J R, Gutterman J U. Neuropsychiatric complications of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252: 938–941
- Renault P F, Hoffnagle J H, Park Y. Psychiatric coniplications of long-term interferon-alpha therapy. Arch Intern Med 1987; 147: 1577–1580
- Livanainen M, Laaksonen R, Niemi M L. Memory and psychomotor impairment following high dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol Scand 1985; 72: 475–480
- Niiranen A, Laaksonen R, Livanainen M. Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatr Scand 1988; 78: 622–626
- Rohatiner A Z, Prior P F, Burton A C. Central nervous system toxicity of interferon. Br J Cancer 1983; 47: 419–422
- Mattson K, Niiranen A. Neurotoxicity of interferon. Cancer Treat Rep 1983; 67: 958–961
- Meyers C A, Scheibel RS., Forman A D. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672–676
- Blalock J E, Smith E M. Human leukocyte interferon (Hu IFN-α); potent cndorphin-like opioid activity. Biochem Biophys Res Commun 1981; 101: 472–478
- Nakashima T, Hori T, Kuriyama K, Kiyohara T. Naloxone blocks the interferon-α induced changes in hypothalamic neuronal activity. Neurosci Lett 1987; 82: 332–336
- De Sarro G B, Masuda Y, Ascioti C. Behavioral and ECoG spectrum changes induced by intracerebral infusion in interferons and interlueukin-2 in rats are antagonized by naloxone. Neuro-pharniacology 1990; 29: 167–179
- Birmanns B, Saphier D, Abramsky O. α-Interferon modifies cortical EEG activity: Dose-dependence and antagonism by naloxone. J Neurol Sci 1990; 100: 22–26
- Dafny N, Prieto-Gomez B, Reyes-Vasquez C. Does the immune system communicate with the central nervous system. J Neuroimmunol 1985; 9: 1–12
- Dafny N. Single injection of three different preparations of a-interferon modifies morphine abstinence signs for a prolonged period. Int J Neurosci 1987; 32: 953–961
- Meyers C A, Mattis P J, Pavol M A, Talpaz M. Pattern of neurobehavioral deficits associated with interferon-a neurotoxicity. Proc Am Assoc Cancer Res 1993; 34: 218
- Blalock J E, Smith E M. Human leukocyte interferon: Structural and biological relatedness to adrenocorticotropic hormone and endorphins. Proc Natl Acad Sci USA 1980; 77: 5922–5974
- Salazar A M, Gibbs C J, Gajdusek C D, Smith R A. Interferons and their applications. Handbook of Experimental Pharmacology, P. Came, W. Carter. Springer-Verlag, Berlin 1984; 471–497
- Smith RA, Landel C, Cornelius C E. Mapping the action of interferon on primate brain. J lnterfer Res 1986; 6: 140, Suppl 2
- Wiranowska M, Wilson T C, Saporta S. Cerebral interferon entry in mice after osmotic alteration of blood-brain barrier. J Interfer Res 1989; 9: 355–362
- Reyes-Vasquez C, Weisbrodt N, Dafny N. Does interferon exert its action through opiate receptors. Life Sci 1985; 35: 1015–1021